硼替佐米对系统性慢性活动性EBV感染的抗肿瘤与抗炎作用
本研究探讨蛋白酶体抑制剂硼替佐米对系统性慢性活动性EBV感染(sCAEBV)的抗肿瘤与抗炎效果。体外实验显示硼替佐米抑制EBV阳性T/NK细胞存活并诱导凋亡,增强内质网应激相关Bip/GRP78表达,激活JNK和p38,抑制NF-κB活化,并降低促炎因子TNF-α和IFN-γ的mRNA表达。在患者细胞构建的异种移植模型中,腹腔注射硼替佐米显著降低外周血EBV-DNA载量和肝脏EBV感染细胞浸润,并降低血清TNF-α和IFN-γ浓度。
要点
- 硼替佐米可诱导sCAEBV患者EBV阳性T/NK细胞凋亡并抑制其存活。
- 硼替佐米通过激活JNK/p38、抑制NF-κB及降低TNF-α/IFN-γ发挥抗炎作用。
- 异种移植模型中硼替佐米降低EBV-DNA载量及肝脏EBV感染细胞浸润。
核心结论
- 硼替佐米对sCAEBV具有抗肿瘤和抗炎双重作用,可能成为减少肿瘤细胞并抑制炎症的治疗选择。
研究设计与样本
- 体外研究使用EBV阳性T/NK细胞系及sCAEBV患者外周血单个核细胞。
- 体内研究使用静脉注射患者细胞构建的sCAEBV异种移植模型。
主要发现
- 硼替佐米抑制EBV阳性T/NK细胞系及患者PBMC中EBV感染T/NK细胞的存活并诱导凋亡。
- 硼替佐米增强内质网应激诱导的Bip/GRP78表达,激活促凋亡分子JNK和p38。
- 硼替佐米抑制EBV阳性T/NK细胞系中组成性活化的生存促进分子NF-κB。
- 硼替佐米降低患者EBV阳性T/NK细胞中促炎细胞因子TNF-α和IFN-γ的mRNA表达。
- 异种移植模型中腹腔注射硼替佐米显著降低外周血EBV-DNA载量及肝脏EBV感染细胞浸润,并降低血清TNF-α和IFN-γ浓度。
临床怎么用
- 硼替佐米可能用于sCAEBV患者以减少肿瘤细胞负荷并抑制炎症,但需临床研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Systemic chronic active Epstein-Barr virus (EBV; sCAEBV) infection, T- and natural killer (NK)-cell type (sCAEBV), is a fatal disorder accompanied by persisting inflammation harboring clonal proliferation of EBV-infected T or NK cells. Today's chemotherapy is insufficient to resolve disease activity and to rid infected cells of sCAEBV. The currently established treatment strategy for eradicating infected cells is allogeneic hematopoietic stem cell transplantation. In this study, we focused on the effects of proteasome inhibitor bortezomib on the disease. Bortezomib suppressed survival and induced apoptosis of EBV+ T- or NK-cell lines and peripheral mononuclear cells containing EBV-infected T or NK cells of sCAEBV patients. Bortezomib enhanced binding immunoglobulin protein/78-kDa glucose-regulated protein (Bip/GRP78) expression induced by endoplasmic reticulum stress and activated apoptosis-promoting molecules JNK and p38 in the cell lines. Bortezomib suppressed the activation of survival-promoting molecule NF-κB, which was constitutively activated in EBV+ T- or NK-cell lines. Furthermore, quantitative reverse transcription-polymerase chain reaction demonstrated that bortezomib suppressed messenger RNA expression of proinflammatory cytokines tumor necrosis factor α (TNF-α) and interferon γ (IFN-γ) in EBV+ T or NK cells from the patients. Finally, we examined the effects of bortezomib using xenograft models of sCAEBV generated by IV injection of patients' cells. The intraperitoneal administration of bortezomib significantly reduced EBV-DNA load in peripheral blood and the infiltration of EBV-infected cells in the models' livers. Moreover, the serum concentration of TNF-α and IFN-γ decreased after bortezomib treatment to the models. Our findings will be translated into the treatment of sCAEBV not only to reduce the number of tumor cells but also to suppress inflammation.
引用
- Yoshimori M, Shibayama H, Imadome KI, et al. Antineoplastic and anti-inflammatory effects of bortezomib on systemic chronic active EBV infection. Blood Adv. 2021. PMID: 33787860. doi:10.1182/bloodadvances.2020002417
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。